Online inquiry

IVTScrip™ mRNA-Anti-KLRC1, IPH-2201(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ9429MR)

This product GTTS-WQ9429MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 0 & 5-Methoxy-UTP. It ecodes the monoclonal antibody that targets KLRC1 gene. The antibody can be applied in Cancers research.
Specifications
Product type mRNA
Modified bases 5-Methoxy-UTP
5' Cap Cap 0
Species Humanized
RefSeq NM_001304448.1
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 3821
UniProt ID P26715
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-KLRC1, IPH-2201(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) (GTTS-WQ9429MR). Click the button above to contact us or submit your feedback about this product.

See other products
CAT Product Name Product Type CDs
GTTS-WQ1561MR IVTScrip™ mRNA-Anti-BMP10&GDF2, ACE-041(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) mRNA ACE-041
GTTS-WQ12866MR IVTScrip™ mRNA-Anti-TLR2, OPN-305(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA OPN-305
GTTS-WQ2351MR IVTScrip™ mRNA-Anti-MS4A1, AME-133v(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) mRNA AME-133v
GTTS-WQ13508MR IVTScrip™ mRNA-Anti-SNCA, PRX002(Cap 0, Pseudo-UTP, 30 nt-poly(A)) mRNA PRX002
GTTS-WQ6873MR IVTScrip™ mRNA-Anti-KLKB1, DX-2930(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) mRNA DX-2930
GTTS-WQ370MR IVTScrip™ mRNA-Anti-ALB&IL6R, 20A11-9mer-ALB11(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA 20A11-9mer-ALB11
GTTS-WQ2192MR IVTScrip™ mRNA-Anti-IL15RA, ALT-803(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA ALT-803
GTTS-WQ3684MR IVTScrip™ mRNA-Anti-MSLN, BAY 2287409(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA BAY 2287409
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW